155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial
In: ESMO Open, Jg. 8 (2023-05-01), Heft 1
Online
academicJournal
Zugriff:
Titel: |
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial
|
---|---|
Autor/in / Beteiligte Person: | Oliveira, M. ; Pascual, T. ; Villacampa, G. ; Munoz, M. ; Martorell, A. Perello ; Lopez, M.E. Perez ; Parraga, K. Amillano ; Farre, X. González ; Vila, C. Martinez ; Ortega, P. Tolosa ; Puy, M. Borrell ; Vila, M. Margeli ; Cejalvo, J.M. ; Zheteyava, Y. ; Sternberg, D.W. ; Fan, P.D. ; Santhanagopal, A. ; Bayona, R. Sanchez ; Ferrero-Cafiero, J.M. ; Prat, A. |
Link: | |
Zeitschrift: | ESMO Open, Jg. 8 (2023-05-01), Heft 1 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 2059-7029 (electronic) |
DOI: | 10.1016/j.esmoop.2023.101494 |
Sonstiges: |
|